Clearpoint Neuro Inc reports results for the quarter ended June 30 - Earnings Summary
12/08/2025 22:00
Clearpoint Neuro Inc CLPT.OQ reported a quarterly adjusted loss of 21 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -16 cents. The mean expectation of two analysts for the quarter was for a loss of 20 cents per share. Revenue rose 17.3% to $9.22 million from a year ago; analysts expected $9.20 million. Clearpoint Neuro Inc's reported EPS for the quarter was a loss of 21 cents. The company reported a quarterly loss of $5.84 million. Clearpoint Neuro Inc shares had fallen by 11.2% this quarter and lost 31.1% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 9.1% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy" Wall Street's median 12-month price target for Clearpoint Neuro Inc is $29.00, about 63.4% above its last closing price of $10.60 This summary was machine generated from LSEG data August 12 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.20 | -0.21 | Missed |
| Mar. 31 2025 | -0.16 | -0.22 | Missed |
| Dec. 31 2024 | -0.16 | -0.20 | Missed |
| Sep. 30 2024 | -0.17 | -0.18 | Missed |